Canadian journal of ophthalmology. Journal canadien d'ophtalmologie最新文献

{"title":"The growing presence of AI-generated content in ophthalmology: a retrospective bibliographic analysis.","authors":"Michael Balas, Xiaole Li, Patrick Ji, Parnian Arjmand","doi":"10.1016/j.jcjo.2025.09.004","DOIUrl":"10.1016/j.jcjo.2025.09.004","url":null,"abstract":"<p><strong>Objective: </strong>To quantify the prevalence and trends of artificial intelligence (AI)-generated content in ophthalmology manuscripts, particularly following the public release of OpenAI's ChatGPT on November 30, 2022.</p><p><strong>Methods: </strong>A retrospective bibliographic analysis was conducted on 1 036 manuscripts from 30 ophthalmology journals, divided into pre-December 2022 (519 manuscripts) and post-December 2022 (517 manuscripts) periods. AI-generated content was evaluated using the Originality Standard 2.0.0 model, which calculates AI probability scores (AIPS) ranging from 0% to 100%. Readability metrics (e.g., Flesch-Kincaid Score) and journal impact metrics (e.g., impact factor) were analyzed.</p><p><strong>Results: </strong>AIPS remained stable from 2014 to 2022 but increased significantly after December 2022 (p < 0.001). The mean AIPS rose from 4.95% in 2022 to 11.2% by mid-2024, with projections estimating 17.51% by mid-2026. Editorials exhibited the highest mean AIPS (12.8%), while surgical technique studies had the lowest (4.33%). Higher AIPS were associated with lower journal impact factors (Spearman's ρ = -0.54; p < 0.001) and simpler language, as reflected by lower Automated Readability Index scores (Spearman's ρ = -0.12; p < 0.005). None of the included manuscripts disclosed AI usage, including 44 manuscripts with AIPS exceeding 25%.</p><p><strong>Conclusions: </strong>AI-generated content in ophthalmology has risen significantly since ChatGPT's release. Higher AIPS correlates with lower journal impact factors and reduced literary complexity. The lack of AI usage disclosure raises ethical concerns and emphasizes the need for transparent reporting and guidelines to ensure the integrity of scientific research.</p>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145184667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transient vision and intraocular pressure changes following anti-vascular endothelial growth factor injection.","authors":"Khaldon Abbas, Amy Basilious, Julie Duncan, Thomas Sheidow, Philip Hooper, John Gonder","doi":"10.1016/j.jcjo.2025.09.005","DOIUrl":"10.1016/j.jcjo.2025.09.005","url":null,"abstract":"<p><strong>Objective: </strong>To assess transient intraocular pressure (IOP) and visual acuity (VA) changes following anti-vascular endothelial growth factor (anti-VEGF) injections and explore factors influencing recovery.</p><p><strong>Design: </strong>A prospective observational study.</p><p><strong>Participants: </strong>Eighty-six patients (100 eyes) receiving anti-VEGF injections with either aflibercept, bevacizumab, or ranibizumab at a retina clinic were included.</p><p><strong>Methods: </strong>Age, biological sex, diagnosis (neovascular age-related macular degeneration, retinal vein occlusion, diabetic macular edema), antiseptic used, anti-VEGF agent, glaucoma status, and IOP-lowering pretreatment were collected. IOP and VA using Snellen charts were measured at baseline, 1, 10, 20, and 30 minutes after injection. Spearman's correlation coefficients were used to assess the relationships between IOP and VA. Ordinal logistic regression was used to evaluate predictors of delayed VA recovery.</p><p><strong>Results: </strong>At 1 minute after intravitreal injection (IVI), VA worsened significantly from a baseline of 0.29 ± 0.21 to 0.76 ± 0.65 logMAR (p < 0.001), while IOP rose from 14.34 ± 4.39 mm Hg to 54.53 ± 20.21 mm Hg (p < 0.001). VA progressively improved over time, with 43% of eyes returning to baseline at 1 minute, 67% at 10 minutes, 83% at 20 minutes, and 89% at 30 minutes. The Spearman correlation coefficient for VA and IOP was statistically significant at 1-minute follow-up after IVI at 0.244 (p = 0.014) but not at later follow-ups. Eyes returning to baseline VA at 1 minute exhibited lower IOP than those not at baseline (p = 0.0004). Logistic regression revealed no significant predictors of delayed VA recovery.</p><p><strong>Conclusions: </strong>Worsened VA and elevated IOP are common in the immediate postinjection period with later improvement. Patients' awareness of VA fluctuations within the first 30 minutes postinjection may aid in the early detection and management of complications associated with IOP elevation.</p>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic status and visual impairment and ocular disease in Canada.","authors":"Angelica Hanna, Diana Lucia Martinez, Iqbal I K Ahmed, Matthew B Schlenker","doi":"10.1016/j.jcjo.2025.09.007","DOIUrl":"10.1016/j.jcjo.2025.09.007","url":null,"abstract":"<p><strong>Objective: </strong>Socioeconomic status (SES) is a known social determinant of general health. The purpose of this review was to explore the association between SES and visual impairment and ocular disease in Canada.</p><p><strong>Methods: </strong>Medline, Embase, CINAHL, and Cochrane were searched from inception to October 2024 for studies that explored the association between SES and visual impairment or ocular disease in Canadian patients. Descriptive statistics were used to summarize the findings. The review was registered in PROSPERO (registration number, CRD42024502490).</p><p><strong>Results: </strong>Twenty-eight studies were included in the review. The included studies covered all provinces and territories and included patients of all ages. Fourteen of the included studies explored the relationship between SES and visual impairment. Eleven of the 14 studies found that patients of lower SES were more likely to have visual impairment, while 3 studies found no significant differences. Fourteen studies have explored the association between SES and various ocular diseases. Glaucoma, macular diseases, diabetic retinopathy, and idiopathic intracranial hypertension were all noted to be of higher prevalence in patients with lower income levels. Patients of lower SES were at the greatest risk of having more severe cataracts (p = 0.001). Among patients with diabetes, those in the lowest SES quintile were at an increased risk of ophthalmological complications compared to higher earners.</p><p><strong>Conclusions: </strong>SES is a determinant of ocular health in Canada. Higher rates of visual impairment and ocular diseases are associated with lower patient socioeconomic status. Efforts are required to mitigate this disparity and improve health equity.</p>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five-year outcomes of a Schlemm's canal microstent (Hydrus Microstent) with cataract surgery in open angle glaucoma: real-world results.","authors":"Ali Salimi, Basma Matar, Paul Harasymowycz","doi":"10.1016/j.jcjo.2025.09.009","DOIUrl":"10.1016/j.jcjo.2025.09.009","url":null,"abstract":"<p><strong>Objective: </strong>To report 5-year real-world outcomes of Hydrus Microstent implantation with cataract surgery (Hydrus+CS) in mild to severe open-angle glaucoma (OAG).</p><p><strong>Design: </strong>A retrospective, consecutive case series.</p><p><strong>Participants: </strong>OAG eyes undergoing Hydrus+CS with 5-year follow-up.</p><p><strong>Methods: </strong>The primary outcome was surgical success using various criteria based on intraocular pressure (IOP) thresholds (≤21, ≤18, and ≤15 mm Hg), stability or reduction in antiglaucoma medication (AGM) use, and absence of secondary glaucoma surgery. Predictors of failure were analyzed using Cox proportional hazard models. Secondary outcomes included changes in IOP, AGM use, vision, and optic nerve structural measures.</p><p><strong>Results: </strong>Sixty-four OAG eyes with a baseline IOP of 17.8 ± 4.6 mm Hg on 2.8 ± 1.1 AGMs were included. Surgical success ranged from 91% to 25%, depending on the criteria. Six eyes (9%) required secondary glaucoma surgery, and selective laser trabeculoplasty (SLT) was performed in 41% of these cases. AGM use decreased without IOP increases in 56% of eyes. Success rates for those maintaining the same or fewer AGMs at IOP thresholds of ≤21, ≤18, and ≤15 mm Hg were 75%, 70%, and 58%, respectively. For those with reduced AGM use, success rates were 61%, 58%, and 45% at the same thresholds. Predictors of failure included higher preoperative IOP (p < 0.001) and post-operative IOP spikes (p = 0.010). IOP decreased by 26%, from 17.8 mm Hg at baseline to 13.2 mm Hg at 5 years, with AGM use declining from 2.8 to 2.2 medications (p < 0.001).</p><p><strong>Conclusions: </strong>This study provides the longest follow-up data on Hydrus+CS, confirming its safety and efficacy in mild to severe OAG.</p>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of triamcinolone acetonide injection for upper eyelid retraction and excursion in active thyroid eye disease.","authors":"Chrisha Faye Habaluyas, Muhammad Abumanhal, Mayari Ito, Yasuhiro Takahashi","doi":"10.1016/j.jcjo.2025.09.002","DOIUrl":"10.1016/j.jcjo.2025.09.002","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of a triamcinolone acetonide (TA) injection for upper eyelid retraction and excursion in patients with active thyroid eye disease (TED).</p><p><strong>Design: </strong>A retrospective observational study.</p><p><strong>Participants: </strong>Fifty-six eyelids of 42 patients with TED who had magnetic resonance imaging-confirmed inflammation of the levator palpebrae superioris (LPS), with or without lacrimal gland (LG) involvement.</p><p><strong>Methods: </strong>Each patient received a transcutaneous injection of 1 mL of TA (40 mg/mL). Clinical outcomes included margin reflex distance-1 (MRD-1), upper eyelid excursion, Hertel exophthalmometry, and clinical activity score (CAS), recorded at baseline, 2 months, and 6 months postinjection. Intraocular pressure (IOP) and adverse events were monitored. Outcomes were compared between patients with inflammation localized in the LPS muscle (LPS group) and those with LPS inflammation, extending to the lacrimal gland (LPS-LG group).</p><p><strong>Results: </strong>All variables improved by 2 months postinjection, and MRD-1 significantly decreased from 5.8 mm at baseline to 4.5 mm at 6 months (p < 0.001). Upper eyelid excursion improved from 12.8 mm to 14.5 mm (p < 0.001). Hertel exophthalmometric values were reduced (16.8 mm to 16.4 mm; p = 0.007). CAS decreased significantly from 1.7 to 0.1 (p < 0.001). No significant differences in treatment outcomes were observed between the LPS and LPS-LG groups. No cases of IOP elevation or post-procedural complications were observed.</p><p><strong>Conclusions: </strong>A transcutaneous TA injection effectively improves upper eyelid retraction and excursion in active TED without significant adverse events.</p>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unilateral nystagmus in a patient with multiple sclerosis.","authors":"Ryan H Kirkpatrick, Farnaz Javadian, Jacob Rullo","doi":"10.1016/j.jcjo.2025.09.016","DOIUrl":"https://doi.org/10.1016/j.jcjo.2025.09.016","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145257385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seropositive neuromyelitis optica spectrum disorder in an 87-year-old patient: remission without immunosuppression.","authors":"Annika Jyothi, Sanjana Jaiswal, Elizabeth O Arogundade, Ritu Sampige, Andrew G Lee","doi":"10.1016/j.jcjo.2025.09.012","DOIUrl":"https://doi.org/10.1016/j.jcjo.2025.09.012","url":null,"abstract":"","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145237824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Canadian ophthalmology workforce trends from 1971 to 2022: longitudinal analysis of age, sex, and distribution compared to other surgical specialties.","authors":"Stuti M Tanya, Raj Pathak, Raheem Remtulla, Armaan Jaffer, Merve Kulbay, Anton Volniansky, Patrick Daigle, Lorne Bellan, Femida Kherani","doi":"10.1016/j.jcjo.2025.09.013","DOIUrl":"https://doi.org/10.1016/j.jcjo.2025.09.013","url":null,"abstract":"<p><strong>Objective: </strong>We describe the evolution of the demographics in the Canadian ophthalmology workforce and compare these trends to other surgical specialists.</p><p><strong>Study design: </strong>A longitudinal observational study.</p><p><strong>Participants: </strong>Surgical specialists identified in the Canadian Institute for Health Information's \"Supply, Distribution, and Migration of Physicians in Canada\" (SDMP) database from 1971 to 2022. Categories included cardiac, general, orthopedic, plastic, and vascular surgery; obstetrics and gynecology; ophthalmology; otolaryngology; and urology.</p><p><strong>Methods: </strong>Demographic data were extracted from the SDMP database. Descriptive statistics were used to determine mean age, male-to-female ratio, urban-to-rural ratio, percentage of physicians under age 40 and above age 65, Canadian-to-foreign trained ratio, and physicians-to-100,000 population ratio for ophthalmologists and other surgeons by decade.</p><p><strong>Results: </strong>Ophthalmologists and other surgeons aged significantly, and ophthalmologists were significantly older than other surgeons (mean age: 52.15 vs 49.73 years; p < 0.01). The percentage above age 65 doubled for both groups, reaching 21.51% for ophthalmologists and 15.31% for other surgeons. Male-to-female ratios decreased 11-fold for ophthalmologists, now 2.54:1, and 17-fold for other surgeons, now 2.01:1. Surgeon-to-100,000 population ratio increased from 22.97 to 25.53 (p < 0.001), whereas ophthalmologist ratios increased slightly from 3.27 to 3.51 (p < 0.001). Urban-to-rural distribution increased by 34.67% for surgeons but decreased by 32.27% for ophthalmologists. Both groups saw an increase in Canadian-trained practitioners, with ratios rising to 5.23:1 for surgeons and 5.41:1 for ophthalmologists by the 2020s.</p><p><strong>Conclusions: </strong>The percentage of ophthalmologists and other surgeons above age 65 years has doubled. Ophthalmologists remain significantly older than other surgeons. The ophthalmologists-to-100,000 population ratio, presently 3.51, meets the recommended goal of 3.37-to-100,000 population.</p>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145237912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extraocular muscle enlargement in thyroid eye disease: a systematic review and meta-analysis.","authors":"Chris Zajner, Angelica Hanna, Michele Zaman, Lulu L C D Bursztyn","doi":"10.1016/j.jcjo.2025.09.014","DOIUrl":"https://doi.org/10.1016/j.jcjo.2025.09.014","url":null,"abstract":"<p><strong>Objective: </strong>While radiographic measurements of orbital structures are used to both diagnose thyroid eye disease (TED) and assess treatment response, the specific extraocular muscle (EOM) changes in TED have not been established. This study aims to systematically review and analyze the difference in EOM sizes in TED patients.</p><p><strong>Design: </strong>Systematic review.</p><p><strong>Methods: </strong>The full protocol was registered on PROSPERO (42024566103). The electronic databases EMBASE, Web of Science, and OVID MEDLINE were searched from inception to June 5, 2024, using keywords related to TED and EOMs. Studies were included if they reported EOM measurements in both a TED group and a control group. Data were analyzed using random-effects model meta-analyses, with subgroup analyses based on EOM measurement parameters (i.e., diameter, cross-sectional area, volume).</p><p><strong>Results: </strong>Twenty-three studies were identified, which together included a total of 2 708 orbits with TED and 1 221 control orbits. Eleven studies were retrospective cohort studies, and 12 were prospective cohort studies. Meta-analysis revealed a mean difference between TED patients and controls in EOM diameter for the inferior rectus of 1.9 mm (95% confidence interval: 1.4-2.3; p < 0.01), medial rectus 1.6 mm (95% CI: 1.1-2.0; p < 0.01), lateral rectus 0.89 mm (95% CI: 0.4-1.4; p < 0.01), and superior rectus 1.3 mm (95% CI: 1.0-1.6; p < 0.01). The mean difference between TED patients and controls in EOM volume for the inferior rectus was 515 mm³ (95% CI: 230-801; p < 0.01), superior rectus was 609 mm³ (95% CI: 327-891; p < 0.01), medial rectus was 551 mm³ (95% CI: 293-810; p < 0.01), and lateral rectus was 288 mm³ (95% CI: 182-393; p < 0.01).</p><p><strong>Conclusions: </strong>Across studies, there is an apparent enlargement of the inferior rectus in TED compared to controls, but the relative extent of involvement of the medial rectus, superior rectus, and lateral rectus is less consistent.</p>","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145237902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Levobupivacaine versus bupivacaine in peribulbar block for ophthalmic surgeries: a systematic review and meta-analysis","authors":"Ali Alkhabbaz ,&nbsp;Mohammad Karam ,&nbsp;Marwa Al Ghafri ,&nbsp;Adam Samet ,&nbsp;Bryan Arthurs ,&nbsp;Christian El-Haddad","doi":"10.1016/j.jcjo.2025.02.011","DOIUrl":"10.1016/j.jcjo.2025.02.011","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To compare the efficacy of levobupivacaine versus bupivacaine for peribulbar block in ophthalmic surgery.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A systematic review and meta-analysis were performed as per the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Publications in MEDLINE, EMBASE, EMCARE, CINAHL, and the Cochrane Central Register of Controlled Trials (CENTRAL) that compared levobupivacaine and bupivacaine for peribulbar block in ophthalmic surgery were screened for eligibility from inception through December 22, 2023. Our analyses were summarized by calculating mean differences (MD) for continuous variables and odds ratios (OR) for dichotomous variables, using either fixed-effects or random-effects meta-analysis based on the level of heterogeneity.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Eight randomized control trials enrolling 800 patients were identified in the English literature published between 1998 and 2023. There was no statistically significant difference in akinesia score at 2 minutes (MD = 0.17; &lt;em&gt;p&lt;/em&gt; = 0.12) or 10 minutes postinjection (MD = 0.02; &lt;em&gt;p&lt;/em&gt; = 0.89). Similarly, there was no statistically significant difference between the 2 groups in terms of time of onset of the anesthetic effect (MD = 0.38; &lt;em&gt;p&lt;/em&gt; = 0.36), postoperative diplopia (OR = 0.62; &lt;em&gt;p&lt;/em&gt; = 0.17), incidence of systemic hypotension (OR = 1.00; &lt;em&gt;p&lt;/em&gt; = 1.00) or verbal pain scales during the block (MD = 0.04; &lt;em&gt;p&lt;/em&gt; = 0.66), at the end of surgery (MD = −0.01; &lt;em&gt;p&lt;/em&gt; = 0.94) or 4 hours postoperatively (MD = −0.00; &lt;em&gt;p&lt;/em&gt; = 0.98).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;As a result of conducting this meta-analysis, we conclude that there is no significant difference between levobupivacaine and bupivacaine in terms of akinesia score, time to onset of anesthetic effect, verbal pain scales, postoperative diplopia, or incidence of systemic hypotension.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectif&lt;/h3&gt;&lt;div&gt;Comparer l’efficacité de la lévobupivacaïne à celle de la bupivacaïne pour réaliser une anesthésie péribulbaire en vue d’une chirurgie ophtalmologique.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;On a procédé à une revue de synthèse systématique de même qu’à une méta-analyse conformément aux lignes directrices PRISMA (&lt;em&gt;Preferred Reporting Items for Systematic Reviews and Meta-Analyses&lt;/em&gt;). On a vérifié l’admissibilité de tous les articles publiés dans MEDLINE, EMBASE, EMCARE, CINAHL et CENTRAL (&lt;em&gt;Cochrane Central Register of Controlled Trials&lt;/em&gt;) comparant la lévobupivacaïne et la bupivacaïne dans l’anesthésie péribulbaire en vue d’une chirurgie ophtalmologique depuis la création des bases de données jusqu’au 22 décembre 2023. Nos analyses ont été résumées en calculant les différences moyennes (DM) pour variables continues et les rapports de cotes (RC) pour variables dichotomiques; on a eu recours à une méta-analyse à effets fixes ou à effets aléatoires selon le degré d’hétérogénéité de","PeriodicalId":9606,"journal":{"name":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","volume":"60 5","pages":"Pages e721-e729"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}